NCT04836897进行中（未招募）不适用
Evaluation of the Efficacy and Safety of the Transcatheter Aortic Valve Replacement System in Patients With Severe Aortic Valve Stenosis Disease at High Surgical Risk
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Freedom from all-cause mortality
研究概览
简要总结
The purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic stenosis who are at high risk of surgery or who are not suitable for surgery.
详细描述
This study is an multicenter, single-arm, prospective, safety and performance clinical study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 65 years ;
- •Patients with symptomatic severe aortic valve stenosis (evaluated by echocardiography: transaortic valve pressure gradient ≥40mmHg (1mmHg=0.133kPa), or transaortic valve blood flow rate ≥4m/s, or aortic Valve area<1.0cm2, or AVA <0.5cm2 /m2);
- •Life expectancy> 12 months;
- •Patients who are anatomically suitable for transcatheter aortic valve implantation;
- •After evaluation by two or more cardiovascular surgeons, patients who are unsuitable for surgery; or patients who refuse surgery after sufficient communication by the surgeons and are at high risk of routine surgery;
- •Patients who can understand the purpose of the trial, voluntarily participate in and signed informed consent form, and are willing to accept relevant examinations and clinical follow-ups.
排除标准
- •Acute myocardial infarction occurred within 1 month before this treatment;
- •Congenital single leaf aortic valve;
- •Any therapeutic cardiac operation (including placement of coronary drug-eluting stents) within 30 days;
- •The patient's heart has been implanted with other artificial heart valves, artificial rings, or severe mitral regurgitation (>3+);
- •Blood system diseases or abnormalities, including leukopenia (WBC<3×109/L), acute anemia (HB <90g/L), thrombocytopenia (PLT<50×109/L), bleeding constitution and coagulopathy ；
- •Untreated severe coronary artery stenosis that requires revascularization;
- •Patients with hemodynamic or respiratory instability, requiring continuous mechanical heart assistance or mechanical ventilation;
- •Patients who need emergency surgery for any reason;
- •Hypertrophic cardiomyopathy with obstruction;
- •Severe left ventricular dysfunction, left ventricular ejection fraction (LVEF) <20%;
- •The echocardiogram indicates the presence of a heart mass, thrombus or vegetation;
- •A history of acute peptic ulcer or upper gastrointestinal bleeding within 3 months;
- •Are allergic to cobalt-chromium alloys or contrast agents, and cannot tolerate anticoagulation and antiplatelet therapy;
- •The diameter of the aortic valve annulus <16mm or >28mm;
- •In any case, patients who refuse surgical treatment in emergency situations;
- •Cerebrovascular accident occurred within 3 months, not including transient ischemic attack;
- •Severe aortic diseases, including abdominal aortic or thoracic aortic aneurysm, obvious curvature of the aortic arch, atherosclerosis of the aortic arch, narrowing of the abdominal or thoracic aorta, and obvious curvature or extension of the thoracic aorta;
- •The iliac-femoral artery is severely obstructed with calcification, severely tortuous or unable to place the 1418F catheter sheath kit;
- •Active infective endocarditis or other active infections;
- •Aortic valve leaflets calcified plaque close to the coronary ostium;
- •Severe disability Alzheimer's disease and unable to take care of oneself in life;
- •Those who have participated in clinical trials of other drugs or medical devices before entering the group and have not yet reached the time limit of the primary research endpoint;
- •The researcher judged that the patient had poor compliance and could not complete the study as required.
结局指标
主要结局
Freedom from all-cause mortality
时间窗: 12 months
All-cause mortality within 12 months of TAVI procedure
次要结局
- Rate of Severe bleeding(30 days、6 months、1-5 years)
- Device success(immediate post-surgical)
- Procedural success(immediate post-surgical)
- Freedom from all-cause mortality(2-5 years)
- Rate of All disabling stroke(30 days、6 months、1-5 years)
- Rate of Myocardial infarction(30 days、6 months、1-5 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Valveclip® Transcatheter Mitral Valve Repair StudyMitral RegurgitationNCT05021614Shanghai NewMed Medical Co., Ltd.150
已完成
不适用
Clinical Trial in China for Aortic Valve StenosisDiseases of Aortic ValveAortic Stenosis DiseaseNCT05607667Genesis Medtech Corporation15
招募中
不适用
Clinical Trial in ChinaDiseases of Aortic ValveAortic Regurgitation DiseaseNCT05580952Genesis Medtech Corporation120
已完成
不适用
Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for MigraineForamen Ovale, PatentMigraineNCT02127294Yi Yang258
已完成
不适用
Transcatheter Aortic Valve Intervention-Live TransmissionAortic Valve DisorderNCT01353287Medstar Health Research Institute110